Ernst & Young is projecting biotech revenues will grow by at least 12% in 2026, recording growth for the third straight year as the industry continues its upswing. “We find ourselves with a biopharma industry that is in a decidedly in a more positive and optimistic position than when we spoke this time last year,” EY analyst Ashwin Singhania said during a media roundtable last week, while cautioning that there are still many challenging headwinds to navigate. Those include economic and political disruption, cost pressures, looming patent cliffs and regulatory uncertainties. Biotech’s effervescent activity has allowed it to overcome the hurdles and sustain momentum into 2026 as the volume and value of licensing and M&A deals continues to increase, EY said.
Read the full article: Fueled by M&A and Partnerships, Biotech Is Poised for Continued Growth: EY //
Source: https://www.fiercebiotech.com/biotech/fueled-ma-and-partnerships-biotech-poised-continued-growth-ey